04/23/2026
This is a bad decision for America: This action sends a misleading message to the public that ma*****na is safe, despite growing evidence linking high-potency THC products to mental health risks, dependency, and impaired cognitive function.
Reclassifying ma*****na to Schedule III prioritizes perception over science. It lowers the guardrails before long-term health impacts are fully understood and risks accelerating commercialization by a rapidly expanding industry that mirrors the tactics once used by Big To***co. Public policy should be guided by rigorous, standardized review through the U.S. Food and Drug Administration—not by fragmented state systems that lack consistency in potency, labeling, and safety oversight.
This decision also fails to address the real-world consequences already seen in states that have loosened ma*****na laws, including increased youth access, higher rates of drug-impaired driving, and the persistence of illegal markets that continue to thrive alongside legal sales. Reclassification does not eliminate these risks—it expands them.
Furthermore, the claim that rescheduling is necessary to advance research is overstated. Research pathways already exist, and the primary barriers have been regulatory complexity and funding—not ma*****na’s classification alone. Moving forward without comprehensive clinical data places both patients and physicians in a position of uncertainty.
National drug policy must prioritize public health, safety, and long-term societal impact over political expediency. We urge policymakers to pause this action and ensure that any future decisions are grounded in sound science, consistent medical standards, and a clear commitment to protecting communities.
Bottom Line: Reclassifying ma*****na as “less dangerous” does not make it safer—it risks normalizing use, expanding access, and exposing more Americans to harm before the science is settled.
